Back to Search Start Over

Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States – a retrospective claims study.

Authors :
Davis, Lori L.
Urganus, Annette
Gagnon-Sanschagrin, Patrick
Maitland, Jessica
Qu, Wendi
Cloutier, Martin
Guérin, Annie
Aggarwal, Jyoti
Source :
Current Medical Research & Opinion. Nov2023, Vol. 39 Issue 11, p1523-1532. 10p.
Publication Year :
2023

Abstract

To describe post-traumatic stress disorder (PTSD)-related symptoms and frequent psychiatric comorbidities, treatments received, healthcare resource utilization (HRU), and healthcare costs pre- and post-PTSD diagnosis among adults in the United States. Adults with PTSD who received a PTSD-related pharmacological treatment (selective serotonin reuptake inhibitor [SSRI], serotonin-norepinephrine reuptake inhibitor [SNRI], atypical antipsychotic [AA]) within 24 months of the first observed PTSD diagnosis (index date) were identified using MarketScan Commercial Database (2015–2020). Study outcomes were assessed during the 6-month pre-diagnosis and 24-month post-diagnosis periods. Subgroup analyses included patients treated or not treated with AAs post-PTSD diagnosis. Of the overall patients (N = 26,306; mean age at diagnosis 39.5 years; 73.3% female), 85.9% had PTSD-related symptoms and frequent psychiatric comorbidities during the 6 months pre-diagnosis. Patients treated with AAs post-PTSD diagnosis (N = 9,298) tended to have higher rates of PTSD-related symptoms and comorbidities at diagnosis than those not treated with AAs (N = 7,011). Following diagnosis, the most commonly observed first-line treatments were SSRI (67.4%), AA (23.4%), and SNRI (22.6%). The rate of PTSD-related symptoms and comorbidities, psychotherapy and pharmacological treatments received, HRU, and healthcare costs increased during the 6 months post-diagnosis relative to the 6 months pre-diagnosis and then declined over time during the 24 months post-diagnosis. The PTSD diagnosis was associated with increased rates of symptoms and frequent psychiatric comorbidities, psychotherapy and pharmacological treatments received, HRU, and healthcare costs, pointing to increased patient monitoring. Within 6 to 12 months after the PTSD diagnosis, these outcomes tended to reduce, perhaps as patients were obtaining targeted and effective care. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03007995
Volume :
39
Issue :
11
Database :
Academic Search Index
Journal :
Current Medical Research & Opinion
Publication Type :
Academic Journal
Accession number :
173858721
Full Text :
https://doi.org/10.1080/03007995.2023.2269839